Guest guest Posted July 11, 2000 Report Share Posted July 11, 2000 VERNON, Conn.--(BUSINESS WIRE)--July 10, 2000 via NewsEdge Corporation - Ohio is the fifteenth state in the nation to pass safety needle legislation. Signed last Thursday by Governor Bob Taft, the Ohio law requires healthcare facilities to provide their employees with safety needles to protect themselves from accidental needlesticks. " Ohio joins California, Tennessee, land, Texas, New Jersey, West Virginia, Minnesota, Maine, Georgia, Iowa, New Hampshire, Alaska, Connecticut, and Oklahoma as states which have demonstrated their commitment to protecting the safety of healthcare workers through the passage of this very important legislation, " according to S. Metz, Bio-Plexus president and CEO. " Bio-Plexus is pleased to join healthcare workers in these states in congratulating the courage and vision displayed by their legislators and governors in passing these laws, " Metz added. On the federal front, healthcare workers unions, medical device manufacturers, and accidental needlestick victims gathered recently for a congressional hearing on the necessity and benefits of a federal needlestick prevention law. The legislation, HB 1899 was introduced by Representative Pete Stark (D-CA) and Marge Roukema (R-NJ) last year. The bill currently has 191 supporters in Congress. Assistant Secretary of Labor N. Jeffress testified before the congressional subcommittee on Workforce Protection that OSHA's Bloodborne Pathogens Standard, introduced in 1991, " among other factors, contributed to the decline (in new cases of hepatitis B among health care workers) - in particular the standard's requirement that employers provide and pay for Hepatitis B vaccines for employees exposed to blood or other potentially infectious materials. " When asked if OSHA's bloodborne pathogens standard and compliance directive protected all healthcare workers, Jeffress acknowledged that public employees (workers in publicly-funded federal and state facilities) were not protected. " Federal OSHA has no jurisdiction over public employees, " Jeffress stated. He added that he supports the legislation because it would also offer protection for public employees across the country. In a statement for the record at the committee hearing, the American Federation of State, County and Municipal Employees (AFSME) declared, " While the compliance directive is an important step, congressional action is needed to further reduce needlestick injuries. One serious limitation on OSHA is the lack of authority to enforce the use of safer devices in state and local government health care workplaces in 27 states and the District of Columbia. This means that public employees in half of the states will remain unprotected by national standards to reduce the transmission of serious and deadly diseases. " " Passage of national legislation is critical to protect the safety of all healthcare workers across the country. Studies show a small but sharp rise in new HIV infections in San Francisco. The rise could signal a new wave of infections - and increased risk for healthcare workers, " Metz continued. " Bio-Plexus Punctur-Guard is the only safety technology available that is made safe during use. This means the clinician should never be exposed to a sharp, blood-contaminated needle after removal from the patient. As Punctur-Guard products get into the hands of healthcare workers, the risk of an accidental needlestick is significantly reduced, and the clinician can more fully concentrate on patient care. We strongly encourage and support legislative action which will help ensure that safe products get into the hands of clinicians, " Metz concluded. Bio-Plexus, Inc. (NASDAQ:BPLX), designs, develops, manufactures and holds U.S. and international patents on safety medical needles and other products under the PUNCTUR-GUARD®, DROP-IT®, and PUNCTUR-GUARD REVOLUTION brand names. In studies by the Centers for Disease Control (MMWR, January 1997) and ECRI (Health Devices, June 1998 and October 1999) PUNCTUR-GUARD® needles ranked highest of all devices studied. Accidental needlesticks number about one million per year in the United States and can result in the transmission of deadly diseases including HIV and Hepatitis B and C. NOTE: THIS PRESS RELEASE MAY CONTAIN FORWARD-LOOKING STATEMENTS AS DEFINED UNDER FEDERAL SECURITIES LAWS, AS AMENDED. FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED BY THE USE OF SUCH TERMINOLOGY AS " BELIEVES, " " EXPECTS, " " MAY, " " WILL, " " SHOULD, " " ANTICIPATES " OR DERIVATIONS OR NEGATIVES THEREOF OR COMPARABLE TERMINOLOGY, OR DISCUSSIONS OF STRATEGY THAT INVOLVES RISKS AND UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS AS A RESULT OF, AMONG OTHER FACTORS, GENERAL ECONOMIC CONDITIONS AND GROWTH IN THE SAFETY MEDICAL PRODUCTS INDUSTRY, COMPETITIVE FACTORS AND PRICING PRESSURES, CHANGES IN PRODUCT MIX, PRODUCT DEMAND, RISK OF DEPENDENCE ON THIRD PARTY SUPPLIERS AND FINANCIERS, ABILITY TO OBTAIN FINANCING, AS WELL AS OTHER FACTORS DESCRIBED FROM TIME TO TIME IN THE COMPANY'S PERIODIC REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION OR DISCUSSED IN OTHER PRESS RELEASES ISSUED BY THE COMPANY. CONTACT: Bio-Plexus, Inc. | Carol Coburn, 860/870-6112 extension 317 | bio.plexus@... ================================= Quote Link to comment Share on other sites More sharing options...
Guest guest Posted July 11, 2000 Report Share Posted July 11, 2000 VERNON, Conn.--(BUSINESS WIRE)--July 10, 2000 via NewsEdge Corporation - Ohio is the fifteenth state in the nation to pass safety needle legislation. Signed last Thursday by Governor Bob Taft, the Ohio law requires healthcare facilities to provide their employees with safety needles to protect themselves from accidental needlesticks. " Ohio joins California, Tennessee, land, Texas, New Jersey, West Virginia, Minnesota, Maine, Georgia, Iowa, New Hampshire, Alaska, Connecticut, and Oklahoma as states which have demonstrated their commitment to protecting the safety of healthcare workers through the passage of this very important legislation, " according to S. Metz, Bio-Plexus president and CEO. " Bio-Plexus is pleased to join healthcare workers in these states in congratulating the courage and vision displayed by their legislators and governors in passing these laws, " Metz added. On the federal front, healthcare workers unions, medical device manufacturers, and accidental needlestick victims gathered recently for a congressional hearing on the necessity and benefits of a federal needlestick prevention law. The legislation, HB 1899 was introduced by Representative Pete Stark (D-CA) and Marge Roukema (R-NJ) last year. The bill currently has 191 supporters in Congress. Assistant Secretary of Labor N. Jeffress testified before the congressional subcommittee on Workforce Protection that OSHA's Bloodborne Pathogens Standard, introduced in 1991, " among other factors, contributed to the decline (in new cases of hepatitis B among health care workers) - in particular the standard's requirement that employers provide and pay for Hepatitis B vaccines for employees exposed to blood or other potentially infectious materials. " When asked if OSHA's bloodborne pathogens standard and compliance directive protected all healthcare workers, Jeffress acknowledged that public employees (workers in publicly-funded federal and state facilities) were not protected. " Federal OSHA has no jurisdiction over public employees, " Jeffress stated. He added that he supports the legislation because it would also offer protection for public employees across the country. In a statement for the record at the committee hearing, the American Federation of State, County and Municipal Employees (AFSME) declared, " While the compliance directive is an important step, congressional action is needed to further reduce needlestick injuries. One serious limitation on OSHA is the lack of authority to enforce the use of safer devices in state and local government health care workplaces in 27 states and the District of Columbia. This means that public employees in half of the states will remain unprotected by national standards to reduce the transmission of serious and deadly diseases. " " Passage of national legislation is critical to protect the safety of all healthcare workers across the country. Studies show a small but sharp rise in new HIV infections in San Francisco. The rise could signal a new wave of infections - and increased risk for healthcare workers, " Metz continued. " Bio-Plexus Punctur-Guard is the only safety technology available that is made safe during use. This means the clinician should never be exposed to a sharp, blood-contaminated needle after removal from the patient. As Punctur-Guard products get into the hands of healthcare workers, the risk of an accidental needlestick is significantly reduced, and the clinician can more fully concentrate on patient care. We strongly encourage and support legislative action which will help ensure that safe products get into the hands of clinicians, " Metz concluded. Bio-Plexus, Inc. (NASDAQ:BPLX), designs, develops, manufactures and holds U.S. and international patents on safety medical needles and other products under the PUNCTUR-GUARD®, DROP-IT®, and PUNCTUR-GUARD REVOLUTION brand names. In studies by the Centers for Disease Control (MMWR, January 1997) and ECRI (Health Devices, June 1998 and October 1999) PUNCTUR-GUARD® needles ranked highest of all devices studied. Accidental needlesticks number about one million per year in the United States and can result in the transmission of deadly diseases including HIV and Hepatitis B and C. NOTE: THIS PRESS RELEASE MAY CONTAIN FORWARD-LOOKING STATEMENTS AS DEFINED UNDER FEDERAL SECURITIES LAWS, AS AMENDED. FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED BY THE USE OF SUCH TERMINOLOGY AS " BELIEVES, " " EXPECTS, " " MAY, " " WILL, " " SHOULD, " " ANTICIPATES " OR DERIVATIONS OR NEGATIVES THEREOF OR COMPARABLE TERMINOLOGY, OR DISCUSSIONS OF STRATEGY THAT INVOLVES RISKS AND UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS AS A RESULT OF, AMONG OTHER FACTORS, GENERAL ECONOMIC CONDITIONS AND GROWTH IN THE SAFETY MEDICAL PRODUCTS INDUSTRY, COMPETITIVE FACTORS AND PRICING PRESSURES, CHANGES IN PRODUCT MIX, PRODUCT DEMAND, RISK OF DEPENDENCE ON THIRD PARTY SUPPLIERS AND FINANCIERS, ABILITY TO OBTAIN FINANCING, AS WELL AS OTHER FACTORS DESCRIBED FROM TIME TO TIME IN THE COMPANY'S PERIODIC REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION OR DISCUSSED IN OTHER PRESS RELEASES ISSUED BY THE COMPANY. CONTACT: Bio-Plexus, Inc. | Carol Coburn, 860/870-6112 extension 317 | bio.plexus@... ================================= Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.